1. Home
  2. ATOM vs CHRS Comparison

ATOM vs CHRS Comparison

Compare ATOM & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atomera Incorporated

ATOM

Atomera Incorporated

HOLD

Current Price

$4.28

Market Cap

157.7M

Sector

Technology

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.15

Market Cap

177.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATOM
CHRS
Founded
2001
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.7M
177.7M
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
ATOM
CHRS
Price
$4.28
$1.15
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $5.51
AVG Volume (30 Days)
404.0K
★ 1.1M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
4.41
★ 472.00
EPS
★ N/A
N/A
Revenue
★ $62,000.00
N/A
Revenue This Year
$527.69
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.89
$1.09
52 Week High
$12.37
$2.62

Technical Indicators

Market Signals
Indicator
ATOM
CHRS
Relative Strength Index (RSI) 46.93 38.06
Support Level $4.19 N/A
Resistance Level $5.06 $1.53
Average True Range (ATR) 0.20 0.09
MACD 0.10 -0.02
Stochastic Oscillator 75.34 1.72

Price Performance

Historical Comparison
ATOM
CHRS

About ATOM Atomera Incorporated

Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: